IDEAYA Biosciences Files 8-K
Ticker: IDYA · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, sec-filing
Related Tickers: IDYA
TL;DR
IDEAYA filed an 8-K, something happened on Sept 7th, details TBD.
AI Summary
IDEAYA Biosciences, Inc. filed an 8-K on September 8, 2025, reporting an "Other Event" on September 7, 2025. The filing does not contain specific details about the event itself, only the standard reporting information for a Form 8-K.
Why It Matters
This filing indicates a material event has occurred that IDEAYA Biosciences is required to report to the SEC, though the specifics are not yet disclosed in this initial filing.
Risk Assessment
Risk Level: low — The filing itself is routine and does not contain negative information; it merely reports that an event occurred.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- September 7, 2025 (date) — Date of earliest event reported
- September 8, 2025 (date) — Date of Report
FAQ
What specific event is IDEAYA Biosciences, Inc. reporting in this 8-K filing?
The filing states "Other Events" as the item information, but does not provide specific details about the event itself in this initial report.
When was the earliest event reported in this filing?
The earliest event reported was on September 7, 2025.
What is the filing date of this 8-K?
The filing was made on September 8, 2025.
What is the principal executive office address for IDEAYA Biosciences, Inc.?
The address is 5000 Shoreline Court, Suite 300, South San Francisco, California 94080.
What is the IRS Employer Identification Number for IDEAYA Biosciences, Inc.?
The IRS Employer Identification Number is 47-4268251.
Filing Stats: 2,209 words · 9 min read · ~7 pages · Grade level 11.7 · Accepted 2025-09-08 06:08:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- d38716d8k.htm (8-K) — 59KB
- 0001193125-25-197605.txt ( ) — 176KB
- idya-20250907.xsd (EX-101.SCH) — 3KB
- idya-20250907_lab.xml (EX-101.LAB) — 18KB
- idya-20250907_pre.xml (EX-101.PRE) — 11KB
- d38716d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of the Company's therapeutics, the IDE397 and Trodelvy combination, and IDE849, including combination therapies; (ii) the timing of and potential of clinical trials to evaluate TOP1-payload based ADCs in SCLC and other DLL3-upregulated solid tumors; (iii) the safety profile of darovasertib; (iv) the timing and content of an update at a later medical conference; (v) the timing of an oral presentation of additional data at ESMO; and (vi) the timing of the selection of a recommended phase 2 dose and the next updated planned for a medical conference regarding IDE397 and Trodelvy. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, and the Company's ability to successfully establish, protect and defend its intellectual property. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed or furnished with the Securities and
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: September 8, 2025 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer